Immunotherapy in ovarian cancer
- User
Immunotherapy in ovarian cancer
- Assistant
Immunotherapy has emerged as a promising approach in the treatment of ovarian cancer, aiming to harness the body's immune system to combat tumor cells. Several strategies are under investigation or have been approved:
1. Antibody-Drug Conjugates (ADCs): ADCs are engineered molecules that combine an antibody specific to cancer cell antigens with a cytotoxic drug. This design allows for targeted delivery of chemotherapy directly to cancer cells, minimizing damage to healthy tissues.
- Elahere (mirvetuximab soravtansine): Elahere is an ADC that targets folate receptor alpha, commonly overexpressed in ovarian cancer cells. In March 2024, the U.S. Food and Drug Administration (FDA) granted full approval for Elahere to treat adults with ovarian, fallopian tube, or abdominal cancer who have undergone one to three prior treatments. This approval was based on data demonstrating its efficacy in this patient population[1].
2. Immune Checkpoint Inhibitors: These therapies work by blocking proteins that inhibit immune responses, thereby enhancing the body's ability to fight cancer.
-
Nivolumab (Opdivo): Nivolumab is a monoclonal antibody that targets the PD-1 receptor, a checkpoint protein on T cells. By inhibiting PD-1, nivolumab enhances T-cell activity against cancer cells. While approved for various cancers, its use in ovarian cancer is still under clinical investigation[2].
-
Ipilimumab (Yervoy): Ipilimumab targets CTLA-4, another checkpoint protein, to boost immune responses against tumors. It has been approved for several cancers, but its role in ovarian cancer treatment is currently being explored in clinical trials[3].
3. Monoclonal Antibodies Targeting CA-125: CA-125 is a protein often elevated in ovarian cancer patients. Therapies targeting this antigen aim to stimulate an immune response against cancer cells expressing CA-125.
-
Oregovomab (OvaRex): Oregovomab is a monoclonal antibody designed to bind to CA-125, facilitating the immune system's recognition and attack of cancer cells. It is currently under clinical development for ovarian cancer treatment[4].
-
Abagovomab: This anti-idiotype monoclonal antibody mimics CA-125, aiming to induce an immune response against ovarian cancer cells. Clinical trials have been conducted to assess its efficacy[5].
4. Oncolytic Viruses: These are engineered viruses that selectively infect and destroy cancer cells while stimulating an immune response.
- Enadenotucirev: An oncolytic adenovirus currently in clinical trials for various cancers, including ovarian cancer. It has been designated as an orphan medicinal product for ovarian cancer treatment by the European Medicines Agency[6].
While these immunotherapeutic approaches offer hope, many are still under investigation, and their efficacy and safety profiles are being evaluated in clinical trials. Patients should consult with their healthcare providers to discuss the most appropriate treatment options based on their individual circumstances.
Recent Developments in Ovarian Cancer Immunotherapy:
- AbbVie's ovarian cancer therapy succeeds in mid-stage trial[7]
- US FDA grants full approval to AbbVie's ovarian cancer therapy[1]
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.